New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:03 EDTBAXBaxter presents data from AHEAD study
Baxter International presented clinical data on Baxter’s leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD study, a four-year outcomes registry of hemophilia A patients treated with ADVATE. These data were presented during the European Association for Haemophilia and Allied Disorders meeting in Brussels, Belgium. These real-world data, which support the clinical experience of prophylaxis treatment with ADVATE, found that the majority of patients (55.3%) on prophylaxis had fewer than two bleeding episodes per year, with a median annual bleed rate of 1.1. Of these patients, 51 percent experienced no bleeds during one year of treatment.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
07:36 EDTBAXInfectious Diseases Society of America to hold a conference
Subscribe for More Information
September 30, 2015
09:29 EDTBAXBaxter agrees to add Third Point representative to board
Subscribe for More Information
09:24 EDTBAXThird Point reaches standstill pact with Baxter, reports 9.9% stake
09:02 EDTBAXBaxter appoints Munib Islam to board; announces agreement with Third Point
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use